While IgG3-driven antibody polyfunctionality was associated with reduced risk of infection in the RV144 vaccine trial [15,16], the specific humoral profiles that associate with antibody-mediated viral containment in the setting of durable control of infection are unknown. Here, IGHG3 is linked to infection.